[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Elisabethinen Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":91},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,38,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100644449","bicmag-study---improving-mineral-buffering-capacity-in-dialysis-patients-100644449",false,"NCT07663279","BicMag Study - Improving Mineral Buffering Capacity in Dialysis Patients","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Prevalent patients (≥ 3 months) treated with thrice weekly hemodialysis or hemodiafiltration\n* Dialysate calcium of 1.25 mmol\u002Fl\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Currently participating in another investigational device or drug study or non-interventional study\n* Dialysate calcium other than 1.25 mmol\u002Fl\n* Parathyroidectomy planned during the study\n* Elective living-donor kidney transplant scheduled during the study period\n* Therapy with bisphosphonates within the past 12 months or denosumab within the past 6 months\n* Pregnant or nursing (lactating) women","ALL","18 Years",{"count":18,"type":19},91,"ESTIMATED","INTERVENTIONAL",[22],"NA","The BicMag study is a prospective, randomized, controlled cross-over study that aims to examine the potential additive effect of a dialysate enriched with both bicarbonate and magnesium on mineral buffering capacity in the blood of chronic hemodialysis patients.",[25],"End Stage Renal Disease","NOT_YET_RECRUITING","2026-06-17",{"date":29,"type":30},"2026-06-23","ACTUAL",{"date":32,"type":19},"2026-10",{"date":34,"type":19},"2029-12",{"name":36,"class":37},"Elisabethinen Hospital","OTHER",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":20,"phases":47,"briefSummary":48,"conditions":49,"keywords":53,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100633750","post-market-registry-of-transbronchial-cryo-assisted-rfa-during-routine-standard-bronchoscopic-tumor-stagng-and-resection-100633750","NCT07530744","Post-Market Registry of Transbronchial Cryo-assisted RFA During Routine Standard Bronchoscopic Tumor Stagng and Resection","Cronos","Inclusion Criteria:\n\n* Solitary nodule ≤ 2.5 cm\n* Candidate for diagnostic bronchoscopy \\& LN staging\n* Eligible for surgical resection\n* Histologically proven lung cancer\n* ≥20 mm margin to pleura\u002Fvessels\u002Fbronchi\n* Signed informed consent, age ≥18 y.\n\nExclusion Criteria:\n\n* Pregnancy\u002Fnursing\n* central tumours abutting vital structures\n* thoracic electronic implants\n* uncorrectable coagulopathy or platelets ≤50 × 10⁹\u002FL\n* severe uncontrolled comorbidities or infection; prior SBRT to zone\n* recent investigational therapy (\\\u003C30 d)\n* atelectasis\u002Fobstructive pneumonitis\u002Feffusion\u002Ffibrosis\n* investigator-determined risk.",{"count":46,"type":19},20,[22],"In order to secure the diagnosis of lung cancer, the investigator will perform a bronchoscopy in order to take tissue samples. These samples will be analyzed in the pathology. This is the routine standard. The aim of the study is to treat the lesion with a device that works both with cold and radiofrequency. The device is already in use for the treatment of lesions. The device allows direct treatment of the lesion during the routine bronchoscopy. As planned, the lesion will then be surgically removed. After the surgery the lesion will be analyzed in the pathology to show the effect of the use of the device. This additional treatment is safe and will support the treatment of the lesion. There are no additional steps or assessments for the participants to undergo.",[50,51,52],"NSCLC","Cryotherapy","RFA",[54],"Tumor Staging and Resection","2026-04-07",{"date":57,"type":30},"2026-04-15",{"date":59,"type":19},"2026-05",{"date":61,"type":19},"2028-10",{"name":36,"class":37},1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":20,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":63},"100546204","phase-3-liquid-biopsy-ctdna-guided-treatment-in-localized-pancreatic-cancer-neoadjuvant-ctx-vs-upfront-surgery-100546204","NCT06391892","Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery","Liquid Biopsy Guided Treatment in Localized Pancreatic Cancer (LIQUIPANC): Circulating Tumor DNA (ctDNA) as Precision Medicine Tool for Stratification of Neoadjuvant Chemotherapy vs. Upfront Surgery","LIQUIPANC","Inclusion Criteria:\n\n* Informed consent\n* \\>18 years old\n* localized pancreatic cancer to go for upfront surgery\n\nExclusion Criteria:\n\n* synchronous secondary malignancy\n* pregnancy","99 Years",{"count":74,"type":19},100,[76],"PHASE3","This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (despite because of CA 19-9 levels and computed tomography, upfront surgery is recommended by tumor board). ctDNA positive patients will receive neoadjvuant chemotherapy at current gold standard physicians choice instead of upfront surgery, because of assumed high biological risk for early recurrence.",[79,80,81],"Pancreatic Cancer","Circulating Tumor Cell","Predictive Cancer Model","RECRUITING","2024-04-25",{"date":85,"type":30},"2024-04-30",{"date":87,"type":30},"2024-01-11",{"date":89,"type":19},"2026-12-31",{"name":36,"class":37},""]